{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:42Z","timestamp":1791500022145,"version":"4.3.4"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Breast cancer is the leading cancer among women globally, and its management typically involves surgery, radiotherapy, and chemotherapy. This combination of complex treatment increases the risk of drug-related problems (DRPs), which can negatively impact the quality of life as it prolongs the hospital stays, increases healthcare costs, and leads to morbidity and mortality. Research on DRPs in the context of breast cancer patients in Nepal is limited; therefore, this study aimed to identify DRPs, assess their prevalence, and examine their associated factors, while emphasizing the importance of pharmaceutical care.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A cross-sectional study was conducted at Bhaktapur Cancer Hospital, Nepal, from February to May 2024. The medical records of 92 patients were reviewed to identify DRPs using the Pharmaceutical Care Network Europe V9.1 tool, along with related scientific literatures and evidence-based guidelines, and verified by two independent medical oncologists. Descriptive statistics were used to summarize the patient characteristics, while the chi-square test was used to evaluate the associations between socio-demographic and clinical characteristics with the presence of DRPs, with a p-value &lt;0.05 considered statistically significant.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>DRPs were identified in 91 of 92 patients (98.9%),\u00a0totaling\u00a0104 events. Most DRPs (87.5%) concerned treatment safety, while 12.5% involved treatment effectiveness. Patient-related factors (43.4%) and drug selection (33.3%) were primary causes. Common adverse effects included alopecia (88.0%) and anorexia (84.8%). A significant association was observed between adverse drug reactions (ADRs) and DRPs (<jats:italic>Fisher\u2019s exact p-value\u2009=\u20090.011<\/jats:italic>).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>DRPs were highly prevalent among breast cancer patients, mainly due to safety issues, with ADRs significantly contributing to it. Findings highlight the need for larger multicentric and cohort studies, and integration of oncology pharmacy services to optimize pharmaceutical care and minimize DRPs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0334703","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:40:57Z","timestamp":1760722857000},"page":"e0334703","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of drug-related problems among breast cancer patients in a cancer specialty center in Nepal"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6024-0044","authenticated-orcid":true,"given":"Aman Kumar","family":"Sah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabin","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Panta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-7294","authenticated-orcid":true,"given":"Shila","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"1","key":"pone.0334703.ref001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cll.2017.10.013","article-title":"Breast cancer in low- and middle-income countries","volume":"38","author":"YM Martei","year":"2018","journal-title":"Clin Lab Med"},{"issue":"3","key":"pone.0334703.ref002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"pone.0334703.ref003","unstructured":"Nepal fact sheet GLOBOCAN. 2022. [cited 2024 Jun 20]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/524-nepal-fact-sheet.pdf"},{"key":"pone.0334703.ref004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/GO.20.00574","article-title":"Epidemiologic Pattern of Cancer in Kathmandu Valley, Nepal: Findings of Population-Based Cancer Registry, 2018","volume":"7","author":"R Subedi","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"pone.0334703.ref005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2231-4040.72251","article-title":"Various types and management of breast cancer: an overview","volume":"1","author":"GN Sharma","year":"2010","journal-title":"J Adv Pharm Technol Res"},{"issue":"1","key":"pone.0334703.ref006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/2211738507666190122111224","article-title":"Drug combinations in breast cancer therapy","volume":"7","author":"FA Fisusi","year":"2019","journal-title":"Pharm Nanotechnol"},{"issue":"3","key":"pone.0334703.ref007","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/10781552241229662","article-title":"Drug-related problems in cancer patients: a systematic review","volume":"30","author":"J Venugopal","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"pone.0334703.ref008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40661-017-0054-9","article-title":"Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya","volume":"4","author":"A Degu","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"pone.0334703.ref009","unstructured":"Dahal P, Venkataraman R, Fuloria P. Assessment of clinical pharmacist intervention in tertiary care teaching hospital of Southern India. 2013."},{"issue":"11","key":"pone.0334703.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309781","article-title":"Drug-related problems among type 2 diabetic patients in Sunwal Municipality of Western Nepal","volume":"19","author":"S Chapagain","year":"2024","journal-title":"PLoS One"},{"key":"pone.0334703.ref011","unstructured":"PCNE Classification for Drug Related Problems V9.1. 2020. [cited 2023 Nov 30]. Available from: https:\/\/www.pcne.org\/upload\/files\/417_PCNE_classification_V9-1_final.pdf"},{"issue":"1","key":"pone.0334703.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245856","article-title":"Factors associated with breast cancer screening intention in Kathmandu Valley, Nepal","volume":"16","author":"D Bhandari","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"pone.0334703.ref013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1078155220914710","article-title":"Drug-related problems and its associated factors among breast cancer patients at the University of Gondar Comprehensive Specialized Hospital, Ethiopia: a hospital-based retrospective cross-sectional study","volume":"27","author":"A Degu","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"pone.0334703.ref014","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/10781552241235898","article-title":"Study to evaluate awareness about medication errors and impact of an educational intervention among healthcare personnel in a cancer hospital","volume":"31","author":"P Kunwor","year":"2025","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"pone.0334703.ref015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/10781552241230631","article-title":"Pediatric oncology services in Nepal: a special focus on pharmacy practice","volume":"30","author":"S Dhungana","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"pone.0334703.ref016","article-title":"Evaluation of quality indicators of breast cancer management at a Tertiary Cancer Center in Nepal","volume":"8","author":"S Baral","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"7624","key":"pone.0334703.ref017","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"E von Elm","year":"2007","journal-title":"BMJ"},{"key":"pone.0334703.ref018","unstructured":"Nepalese National Formulary (NNF) 2018, Department of Drug Administration. [cited 2025 May 28]. Available from: https:\/\/www.dda.gov.np\/content\/nepalese-national-formulary-nnf"},{"key":"pone.0334703.ref019","unstructured":"National List of Essential Medicines Nepal 2021, Sixth revision, Department of Drug Administration. [cited 2025 May 28]. Available from: https:\/\/dda.gov.np\/events\/national-list-of-essential-medicines-nepal-sixth-revision-2021"},{"issue":"20","key":"pone.0334703.ref020","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"pone.0334703.ref021","article-title":"Clinicopathological profile of breast cancer in young females at tertiary cancer center in Nepal","volume":"7","author":"G Pandey","year":"2023","journal-title":"Nepal J Cancer"},{"key":"pone.0334703.ref022","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/2347-5625.189818","article-title":"Problems of breast cancer survivors living in an urban area of Nepal","volume":"3","author":"A Sapkota","year":"2016","journal-title":"Asia-Pac J Oncol Nurs"},{"issue":"1","key":"pone.0334703.ref023","article-title":"Drug therapy problems and clinical outcomes among patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer on trastuzumab-based therapy in a Kenyan tertiary health facility","volume":"7","author":"G Kc","journal-title":"J Cancer Sci Clin Oncol"},{"issue":"8","key":"pone.0334703.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255499","article-title":"Cancer burden in Nepal, 1990\u20132017: an analysis of the Global Burden of Disease study","volume":"16","author":"G Shrestha","year":"2021","journal-title":"PLoS ONE"},{"issue":"1","key":"pone.0334703.ref025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0344-0338(11)81015-0","article-title":"Left and right sided breast cancer","volume":"186","author":"H Tulinius","year":"1990","journal-title":"Pathol Res Pract"},{"issue":"2","key":"pone.0334703.ref026","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-010-1173-8","article-title":"Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry","volume":"127","author":"ML Telli","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"pone.0334703.ref027","article-title":"Impact of a medication therapy management service offered to patients in treatment of breast cancer","volume":"54","author":"PAD Amaral","year":"2018","journal-title":"Braz J Pharm Sci"},{"issue":"9","key":"pone.0334703.ref028","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.7314\/APJCP.2013.14.9.5095","article-title":"Breast cancer in young women from a low risk population in Nepal","volume":"14","author":"B Thapa","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"pone.0334703.ref029","first-page":"252","article-title":"Management of breast cancer in Nepal","volume":"48","author":"Y Singh","year":"2009","journal-title":"JNMA J Nepal Med Assoc"},{"issue":"22","key":"pone.0334703.ref030","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.7150\/jca.44768","article-title":"The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis","volume":"11","author":"S Guo","year":"2020","journal-title":"J Cancer"},{"issue":"3","key":"pone.0334703.ref031","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3747\/co.23.3004","article-title":"Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age","volume":"23","author":"S Lupichuk","year":"2016","journal-title":"Curr Oncol"},{"issue":"4","key":"pone.0334703.ref032","first-page":"527","article-title":"Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer","volume":"2","author":"M Martin","year":"2006","journal-title":"Womens Health"},{"key":"pone.0334703.ref033","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e11106","article-title":"Docetaxel\/doxorubicin\/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: results from a single institution","volume":"28","author":"ZG Surmeli","year":"2010","journal-title":"J Clin Oncol"},{"key":"pone.0334703.ref034","doi-asserted-by":"crossref","first-page":"1184472","DOI":"10.3389\/fphar.2023.1184472","article-title":"A review of FDA approved drugs and their formulations for the treatment of breast cancer","volume":"14","author":"M Chaurasia","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0334703.ref035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s41687-024-00790-0","article-title":"Exploring the factors influencing the health-related quality of life in patients experiencing adverse drug reactions: a cross-sectional study","volume":"8","author":"G Pavan","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"pone.0334703.ref036","doi-asserted-by":"crossref","DOI":"10.1016\/S1386-5056(99)00020-9","article-title":"Detecting adverse drug reactions to improve patient outcomes","volume":"55","author":"TJ Hannan","year":"1999","journal-title":"Int J Med Inf"},{"issue":"2","key":"pone.0334703.ref037","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4274\/tjps.galenos.2025.44902","article-title":"Integrating a pharmacovigilance and response unit team for a better adverse drug reaction reporting and management: insights from a prospective cross-sectional study","volume":"22","author":"V Mugada","year":"2023","journal-title":"Turk J Pharm Sci"},{"issue":"4","key":"pone.0334703.ref038","article-title":"The incidence and severity of patient-reported side effects of chemotherapy in routine clinical care: a prospective observational study","volume":"15","author":"B Katta","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"pone.0334703.ref039","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.21608\/ejhm.2022.260758","article-title":"A pharmaceutical care plan to minimize the incidence of potential drug-related problems in cancer patients","volume":"89","author":"S Nabil","year":"2022","journal-title":"Egypt J Hosp Med"},{"key":"pone.0334703.ref040","first-page":"100302","article-title":"A Clinical pharmacist-led approach on reducing drug related problems among patients with neurological disorders: an interventional study","volume":"11","author":"N Jimmy","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"key":"pone.0334703.ref041","unstructured":"Dahal P, Venkataraman R, Fuloria P. Assessment of clinical pharmacist intervention in tertiary care teaching hospital of Southern India. 2013."},{"issue":"1","key":"pone.0334703.ref042","doi-asserted-by":"crossref","first-page":"2288603","DOI":"10.1080\/20523211.2023.2288603","article-title":"Drug-related problems identified by clinical pharmacists in an academic medical centre in Thailand","volume":"17","author":"N Lekpittaya","year":"2023","journal-title":"J Pharm Policy Pract"},{"issue":"8","key":"pone.0334703.ref043","doi-asserted-by":"crossref","first-page":"8701","DOI":"10.21037\/apm-21-817","article-title":"Drug-related problems identified by clinical pharmacists in nephrology department of a tertiary hospital in China-a single center study","volume":"10","author":"X-X Liu","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"1","key":"pone.0334703.ref044","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40360-021-00530-w","article-title":"Identification and solution of drug-related problems in the neurology unit of a tertiary hospital in China","volume":"22","author":"P Liu","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"pone.0334703.ref045","doi-asserted-by":"crossref","first-page":"6785835","DOI":"10.1155\/2020\/6785835","article-title":"Identification and resolution of drug-related problems among childhood cancer patients in Ethiopia","volume":"2020","author":"MB Yismaw","year":"2020","journal-title":"J Oncol"},{"issue":"5","key":"pone.0334703.ref046","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/10781552231174784","article-title":"Clinical clerkship at an oncology hospital based on the curriculum of a clinical pharmacy program from a university belonging to low-middle-income country: insights from a pharmacy program experience","volume":"29","author":"N Pathak","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"pone.0334703.ref047","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/00185787241306689","article-title":"Establishment of a Drug Information Unit and Pharmacovigilance Cell in a Provincial Hospital of Nepal: Implementation of the 2015 Hospital Pharmacy Service Guidelines","volume":"60","author":"N Pathak","year":"2025","journal-title":"Hosp Pharm"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:41:07Z","timestamp":1760722867000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334703"}},"subtitle":[],"editor":[{"given":"Vijayaprakash","family":"Suppiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334703","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}